In a regulatory filing on the BSE, the city-based leading contract research and manufacturing firm said net profit, however, grew 3 per cent annually to Rs 77 crore for the quarter under review from Rs 75 crore in the like period year ago.
Earnings before interest, tax, depreciation and amortisation (Ebitda) grew 7 per cent annually to Rs 130 crore from Rs122 crore year ago, while its margin declined marginally to 37 per cent from 38 per cent year ago.
"We have posted a consecutive quarter of accelerating revenue growth. Our chemical development and dedicated centre verticals continue to put up sustained performance and drive our growth," said Syngene Chief Executive Officer Jonathan Hunt in a statement here.
As part of its capex investment plan, the company added 76-bed capacity to the human pharmacology unit for enabling its clinical development team to meet growing customer demand.
The new facility has dedicated areas for drug administration, phlebotomy, dining, recreation and resting, 24x7 supervision by a team of physicians and staff nurses and a paperless system for recording study data.
"With the expansion, the unit has 190 beds to help our clinical development business meet the demand for its services," added the statement.
The company also incorporated a wholly-owned overseas subsidiary in the US to provide footing in the local market and allow North American clients access to its business teams.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
About VDC
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.